Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
12
Number of overlapping holdings
14.6%
% of AGNG's 82 holdings also in CANC
24.0%
% of CANC's 50 holdings also in AGNG
Overlap by Weight
Sector Drift (AGNG minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in AGNG |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
CHUGAI PHARMACEUTICAL CO LTD | 4.1% | 3.4% | 3.4% |
 |
ELI LILLY & CO | 3.1% | 5.3% | 3.1% |
|
BRISTOL-MYERS SQUIBB CO | 3.1% | 3.7% | 3.1% |
|
AMGEN INC | 3.1% | 3.2% | 3.1% |
|
BEIGENE LTD. SPONSORED ADR | 2.0% | 3.9% | 2.0% |
Position Highlights (Non-Overlapping Exposures)
AGNG Overweight Relative to CANC
|
WELLTOWER, INC. | 4.5% |
|
BOSTON SCIENTIFIC CORP | 4.1% |
 |
ROCHE HOLDING AG-BR | 3.1% |
 |
UCB SA | 3.1% |
|
STRYKER CORP | 3.0% |
|
ALCON, INC. | 3.0% |
 |
MEDTRONIC PLC | 3.0% |
|
JOHNSON & JOHNSON | 3.0% |
 |
ASTRAZENECA PLC-SPONS ADR | 2.9% |
 |
CELLTRION INC | 2.3% |
AGNG Underweight Relative to CANC
|
ASTRAZENECA PLC | -5.6% |
|
BRIDGEBIO PHARMA, INC. | -5.2% |
|
MERCK & CO. INC. | -4.2% |
|
REVOLUTION MEDICINES, INC. | -4.0% |
 |
GENMAB A/S SPONSORED ADR | -3.9% |
|
ROCHE HOLDINGS LTD-SPONS ADR | -3.9% |
|
NOVARTIS AG | -3.5% |
|
NUVALENT, INC. CLASS A | -3.1% |
|
LEGEND BIOTECH CORPORATION SPONSORED | -3.0% |
|
EXELIXIS INC | -2.9% |